Literature DB >> 19697104

Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT.

R Golfieri1, E Marini, A Bazzocchi, F Fusco, F Trevisani, C Sama, G Mazzella, S Cavuto, F Piscaglia, L Bolondi.   

Abstract

PURPOSE: We prospectively compared gadoliniumenhanced magnetic resonance imaging (dynamic MRI), superparamagnetic iron oxide (SPIO) (ferucarbotran) MRI and multidetector-row computed tomography (MDCT) and the combination of dynamic MRI plus MDCT vs. dynamic MRI plus SPIO-MRI (double-contrast MRI: DC-MRI) for the detection of small (<or=3 cm) hepatocellular carcinomas (HCCs).
MATERIALS AND METHODS: Sixty-three patients with liver cirrhosis and suspicious nodules detected during ultrasound (US) surveillance underwent DC-MRI in the same imaging session and MDCT within 15 days. The final diagnosis was established at pathology on the explanted liver (n=10), resection (n=6) and biopsy (n=38) specimens or at 2-years' follow-up (n=9).
RESULTS: One hundred and twenty-three nodules were detected: 87 were confirmed HCCs in 54 patients. The accuracy of SPIO-MRI and dynamic MRI were similar, both being superior to MDCT. Dynamic MRI demonstrated the highest sensitivity (83.9%; p<0.001). especially for lesions <1 cm (90.6%) - coupled with a lower specificity (36.1%) than SPIO-MRI, particularly in subcentimeter lesions (28.6%). SPIO-MRI demonstrated the highest sensitivity for nodules >1 cm and the highest specificity (83.3%) superior to dynamic MRI (p<0.0001). In the per-lesion analysis, SPIO-MRI demonstrated a positive predictive value higher than dynamic MRI (p=0.0059) and than both the combinations dynamic MRI/MDCT and DC-MRI (p=0.0021 and p=0.0087, respectively). DC-MRI showed the highest sensitivity (97.7%) and accuracy (78.9%), detecting hypovascular and atypical HCCs >1 cm. Furthermore its per-patient negative predictive value was the highest (100%), and significantly higher than all the other methods.
CONCLUSIONS: DC-MRI is the most sensitive and accurate method and can be confidently used as a single-step procedure for the detection of small HCCs, with the exception of lesions <1 cm.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19697104     DOI: 10.1007/s11547-009-0439-x

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  48 in total

Review 1.  Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view.

Authors:  Masamichi Kojiro
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

2.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

3.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Authors:  Jorge A Marrero; Hero K Hussain; Hahn V Nghiem; Ramsey Umar; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

4.  Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.

Authors:  Y Tang; Y Yamashita; A Arakawa; T Namimoto; K Mitsuzaki; Y Abe; K Katahira; M Takahashi
Journal:  AJR Am J Roentgenol       Date:  1999-06       Impact factor: 3.959

5.  Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Dongil Choi; Seung Hoon Kim; Jae Hoon Lim; Won Jae Lee; Min Ju Kim; Hyo K Lim; Soon Jin Lee
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

6.  Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue.

Authors:  Bobby Bhartia; Janice Ward; J Ashley Guthrie; Philip J Robinson
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

7.  Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US.

Authors:  Thomas J Vogl; Wolfram Schwarz; Stefan Blume; Michael Pietsch; Kohkan Shamsi; Martina Franz; Hartmut Lobeck; Thomas Balzer; Kelly del Tredici; Peter Neuhaus; Roland Felix; Renate M Hammerstingl
Journal:  Eur Radiol       Date:  2002-09-10       Impact factor: 5.315

8.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT.

Authors:  Bo Kiung Kang; Jae Hoon Lim; Seung Hoon Kim; Dongil Choi; Hyo Keun Lim; Won Jae Lee; Soon Jin Lee
Journal:  Radiology       Date:  2003-01       Impact factor: 11.105

10.  Cirrhosis or chronic hepatitis: evaluation of small (<or=2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging.

Authors:  Ayame Shimizu; Katsuyoshi Ito; Shinji Koike; Takeshi Fujita; Kensaku Shimizu; Naofumi Matsunaga
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

View more
  8 in total

1.  Preliminary experience with abdominal dual-energy CT (DECT): true versus virtual nonenhanced images of the liver.

Authors:  C N De Cecco; V Buffa; S Fedeli; A Vallone; R Ruopoli; M Luzietti; V Miele; M Rengo; M Maurizi Enrici; P Fina; A Laghi; V David
Journal:  Radiol Med       Date:  2010-09-17       Impact factor: 3.469

2.  Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.

Authors:  Jonathan G Sham; Forrest M Kievit; John R Grierson; Peter A Chiarelli; Robert S Miyaoka; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

Review 3.  Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Vanja Giljaca; Agostino Colli; Mirella Fraquelli; Giovanni Casazza; Damir Miletic; Davor Štimac
Journal:  Cochrane Database Syst Rev       Date:  2021-10-06

Review 4.  The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.

Authors:  Xi Chen; Mingkai Li; Ruomi Guo; Weimin Liu; Jianwen Li; Xiaodan Zong; Qilong Chen; Jin Wang
Journal:  Abdom Radiol (NY)       Date:  2022-03-21

5.  Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.

Authors:  Jonathan G Sham; Forrest M Kievit; John R Grierson; Robert S Miyaoka; Matthew M Yeh; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park
Journal:  J Nucl Med       Date:  2014-03-13       Impact factor: 10.057

6.  MRI of Focal Liver Lesions.

Authors:  Nils Albiin
Journal:  Curr Med Imaging Rev       Date:  2012-05

7.  APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.

Authors:  Cher Heng Tan; Su-Chong Albert Low; Choon Hua Thng
Journal:  Int J Hepatol       Date:  2011-04-19

8.  Evaluation of non-targeting, C- or N-pH (low) insertion peptide modified superparamagnetic iron oxide nanoclusters for selective MRI of liver tumors and their potential toxicity in cirrhosis.

Authors:  Abdulrahman Ahmed Mahmood; Jianqi Zhang; Rufang Liao; Xiwei Pan; Dan Xu; Haibo Xu; Qibing Zhou
Journal:  RSC Adv       Date:  2019-05-07       Impact factor: 4.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.